Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24424824 | 0.89 | CA12 (0.44) | CA12CA2CA3CA4CA6 | |
| SCHEMBL10086102 | 0.85 | S1PR2 (0.35) | CA12CA2CA3CA4CA6 | |
| SCHEMBL1043900 | 0.83 | — | — | |
| SCHEMBL24424952 | 0.81 | CA12 (0.61) | CA12CA2CA3CA4CA6 | |
| SCHEMBL173215 | 0.81 | CA12 (0.32) | CA12CA2CA3CA4CA6 | |
| SCHEMBL24515159 | 0.80 | KDM4E (0.37) | CA12CA2CA3CA4CA6 | |
| SCHEMBL27418875 | 0.80 | CYP2C9 (0.31) | — | |
| SCHEMBL8909834 | 0.80 | MEN1 (0.35) | — | |
| SCHEMBL5715864 | 0.80 | CA12 (0.53) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29580954 | 0.80 | CA12 (0.53) | CA12CA2CA3CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| WO-2018227012-A9 | POLYMER-LIPID MATERIALS FOR DELIVERY OF NUCLEIC ACIDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-11-14 | — | — | WO | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | CA12 1065/4885CA2 369/4885CA3 1324/4885 |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | CA12 4592/4885CA2 3504/4885CA3 4815/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | CA12 4592/4885CA2 3504/4885CA3 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.